BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33575974)

  • 1. Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.
    Moura MM; Cabrera RA; Esteves S; Cavaco BM; Soares P; Leite V
    J Endocrinol Invest; 2021 Sep; 44(9):1837-1846. PubMed ID: 33575974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
    Zhou Q; Yue S; Cheng Y; Jin J; Xu H
    Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation.
    Qi XP; Lin GB; Chen B; Li F; Cao ZL; Zheng WH; Zhao JQ
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):554-560. PubMed ID: 32660411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in Medullary Thyroid Carcinoma in
    Mathiesen JS; Nielsen SG; Rasmussen ÅK; Kiss K; Wadt K; Hermann AP; Nielsen MF; Larsen SR; Brusgaard K; Frederiksen AL; Godballe C; Rossing M
    Front Endocrinol (Lausanne); 2020; 11():251. PubMed ID: 32411094
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
    Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
    Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
    [No Abstract]   [Full Text] [Related]  

  • 6. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
    Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
    Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
    Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
    Frank-Raue K; Raue F
    Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
    Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel RET mutations in macedonian patients with medullary thyroid carcinoma: genotype-phenotype correlations.
    Jovanovic R; Kostadinova-Kunovska S; Janevska V; Bogoeva B; Spasevska L; Miladinova D; Ugrinska A; Zdraveska-Kochovska M; Trajkov D; Petrusevska G
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):93-107. PubMed ID: 26076779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
    Chu YH; Lloyd RV
    Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
    Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
    J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.
    Oczko-Wojciechowska M; Swierniak M; Krajewska J; Kowalska M; Kowal M; Stokowy T; Wojtas B; Rusinek D; Pawlaczek A; Czarniecka A; Szpak-Ulczok S; Gawlik T; Chmielik E; Tyszkiewicz T; Nikiel B; Lange D; Jarzab M; Wiench M; Jarzab B
    Sci Rep; 2017 Feb; 7():42074. PubMed ID: 28181547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
    Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
    Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
    Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ
    Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.